Xolair® (omalizumab)
More information
These links will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Summary of Product Characteristics (SmPC) for the 75 mg pre-filled syringe and autoinjector pen, 150 mg pre-filled syringe and autoinjector pen, and 300 mg pre-filled syringe and autoinjector pen for Xolair.
Patient Information Leaflet (PIL) for the 75 mg pre-filled syringe and autoinjector pen, 150 mg pre-filled syringe and autoinjector pen, and 300 mg pre-filled syringe and autoinjector pen for Xolair.
UK | March 2025 | FA-11324017
Reporting side-effects
If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side-effects you can help provide more information on the safety of your medication.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.